The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 147-154

  Lv, Yijing ^a   Yuan, Cunzhong ^a   Xiao, Xiaoyan ^a   Wang, Xuping ^a   Ji, Xuming ^b   Yu, Huayun ^b   Wu, Zhichun ^b   Zhang, Jidong ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Enhancer of zeste homolog 2; Lung adenocarcinoma; Short hairpin RNA

Indexed keywords

CISPLATIN; HISTONE METHYLTRANSFERASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR EZH2 INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DRUG SENSITIVITY; EZH2 GENE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENDER; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMOKING HABIT;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 84861557861     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1787     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Travis WD: Pathology of lung cancer. Clin Chest Med 32: 669-692, 2011.
3. Montesinos J, Bare M, Dalmau E, et al: The changing pattern of non-small cell lung cancer between the 90 and 2000 decades. Open Respir Med J 5: 24-30, 2011.
4. Charloux A, Quoix E, Wolkove N, Small D, Pauli G and Kreisman H: The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26: 14-23, 1997. (Pubitemid 27129564)
5. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
6. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003. (Pubitemid 37205983)
7. Bachmann IM, Halvorsen OJ, Collett K, et al: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273, 2006. (Pubitemid 46622055)
8. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
9. Rizzo S, Hersey JM, Mellor P, et al: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10: 325-335, 2011.
10. Berger W, Elbling L and Micksche M: Expression of the major vault protein LRP in human non-small cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 88: 293-300, 2000.
11. Ikuta K, Takemura K, Sasaki K, et al: Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 28: 707-712, 2005. (Pubitemid 40879942)
12. Kourti M, Vavatsi N, Gombakis N, et al: Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 86: 166-173, 2007. (Pubitemid 47425197)
13. Yuan C, Jiao L, Yang L, et al: The up-regulation of 14-3-3 proteins in Smad4 deficient epidermis and hair follicles at catagen. Proteomics 8: 2230-2243, 2008. (Pubitemid 351898029)
14. Liu H, Wang P, Song W and Sun X: Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways. FASEB J 23: 3383-3392, 2009.
15. Kuzmichev A, Jenuwein T, Tempst P and Reinberg D: Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 14: 183-193, 2004. (Pubitemid 38515646)
16. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K and Yokozaki H: Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97: 484-491, 2006. (Pubitemid 43811589)
17. Breuer RH, Snijders PJ, Smit EF, et al: Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6: 736-743, 2004. (Pubitemid 40041491)
18. Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell 118: 409-418, 2004. (Pubitemid 39485661)
19. Sasaki M, Ikeda H, Itatsu K, et al: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882, 2008.
20. Kikuchi J, Kinoshita I, Shimizu Y, et al: Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 116: 3015-3024, 1915.
21. Yu J, Cao Q, Mehra R, et al: Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12: 419-431, 2007. (Pubitemid 350046407)
22. Fujii S and Ochiai A: Enhancer of zeste homolog 2 down-regulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 99: 738-746, 2008. (Pubitemid 351448078)
23. Cao Q, Yu J, Dhanasekaran SM, et al: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274-7284, 2008.
24. Hussain M, Rao M, Humphries AE, et al: Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 69: 3570-3578, 2009.
25. Abbosh PH, Montgomery JS, Starkey JA, et al: Domin-antnegative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66: 5582-5591, 2006. (Pubitemid 43927108)
26. Hu S, Yu L, Li Z, et al: Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10: 788-795, 2010.
27. Ougolkov AV, Bilim VN and Billadeau DD: Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 14: 6790-6796, 2008.